

ST PHARM IR BOOK

2026 1st Quarter Earnings Release

Cautionary Statement regarding Forward-looking Statements

This presentation contains forward-looking statements from Dong-A Socio Group ("the Group") that include, but are not limited to, statements regarding our future financial performance, business strategies, market opportunities, product development, and operational plans. Words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "project," "will," and similar expressions are intended to identify such forward-looking statements.


These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effects on the Group. Such forward-looking statements are inherently subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed in these forward-looking statements.

We caution investors not to place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Additionally, please note that the financial figures and metrics presented in these Investor Relations materials are preliminary and have not yet been audited by an independent auditor. These numbers may be subject to change in future finalized disclosures.

2026 1st Quarter Financial Results

Preliminary Consolidated Earnings

(Unit : 1 Billion KRW)



* "Etc." includes revenues from CRO subsidiaries, mRNA, etc.

Statement

Revenue ₩67.0 Billion, OP ₩11.5 Billion, NI ₩15.2 Billion

- 1) High-margin product sales and strong USD largest contribution to profit growth
- 2) Robust margins despite increased costs (R&D expense, raw material costs, etc.)
- 3) Revenue growth and improved profitability from CROs during 1Q

(Unit : 1 Billion KRW)

	'26.1Q	'25.1Q	2025	YoY
Revenue	67.0	52.4	331.7	27.7%
Cost of Goods Sold	35.8	33.2	195.5	8.1%
Gross Profit	31.1	19.3	136.2	61.6%
SG&A Expenses	19.6	18.2	81.3	7.4%
R&D Expenses	6.5	5.5	23.7	18.0%
Operating Profit	11.5	1.0	54.9	1024.6%
Net Income	15.2	0.7	54.6	2044.8%
Gross Profit Margin	46.5%	36.8%	41.1%	+9.7%p
Operating Profit Margin	17.2%	2.0%	16.6%	+15.3%p
Net Income Margin	22.7%	1.4%	16.5%	+21.3%p

2026 1st Quarter Financial Results


Segment Breakdown

(Unit : 1 Billion KRW)

Segments		'25.1Q	'25.2Q	'25.3Q	'25.4Q	'26.1Q	YoY
Oligo	Total	37.6	43.5	68.6	87.9	40.4	+7.5%
	Comm.	32.4	37.2	34.1	70.6	27.1	-16.5%
	Clinical	5.1	6.3	34.5	17.4	13.3	+158.9%
Small Molecule		1.1	6.7	0.1	18.4	4.6	+301.6%
mRNA, etc.		0.6	0.7	1.4	0.4	0.9	+53.8%
Generic		5.3	8.9	2.4	9.0	9.7	+81.1%
Separate		44.7	59.8	72.6	116.1	56.0	+25.4%
Subsidiaries		7.7	8.4	9.3	13.0	10.9	+41.1%
Consolidated		52.4	68.3	81.9	129.1	67.0	+27.7%

Backlog Trend

(Unit : 1 Million USD)



* Backlog may be subject to change depending on future currency exchange rates assumptions, shipment schedule, etc. (Assume 1 CHF = 1.2 USD)

Statement

Sales Details

- Oligonucleotide CDMO
Commercial project sales accounted for 67%
Portfolio diversification continued with sales from 4 new clinical projects
- Small Molecule CDMO
2 major commercial projects to lead annual sales growth
- mRNA etc.
First sales recognition from new early-stage sgRNA project

Backlog Status

- Total backlog valued at approx. 326 Mil. USD (commercial project +80%)
- Oligo backlog valued at 250 Mil. USD, SM at 65 Mil. USD

Anticipated Events

- STP-0404(Pirmitegravir) Ph2a Topline results expected during 3Q
- ≈ 5 approvals (NDA / indication expansion) within current portfolio expected within 3 years from Oligo & SM

2026 1st Quarter Financial Results

- Oligo sales forecast unchanged for 2026 despite partial delay. Delayed shipments scheduled within 2Q
- Revenue mix of Oligo expected to be less than 2025 due newly added/approved commercial SM projects. Mid to long term portion expected to be +70%
- Increased cost affected by Mid-East conflict remains manageable. (\approx 7% of 2025 annual SG&A Expenses)
Secured year-long agreements with raw material suppliers (77% domestic suppliers)
- R&D expense to increase vs. 2025; ongoing clinical trial, new personnel to support CMC projects, etc.

Thank You
